ERBB2 and metastatic neoplasm: In our study, the changing rates between metastatic lesions and primary lesions for ER, PR, and HER-2 expression in 34 metastatic tumors were 32.3% (11/34), 47% (16/34), and 14.7% (5/39) respectively, and the changing rate in the molecular subtype was 54.3% (19/39), a finding that was basically consistent with that in literature reports [6, 26].